Daniel Stauder
Stock Analyst at Citizens
(4.12)
# 504
Out of 5,105 analysts
20
Total ratings
57.89%
Success rate
15.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $45.12 | +17.46% | 7 | Nov 7, 2025 | |
| ATRC AtriCure | Reiterates: Market Outperform | $60 | $42.38 | +41.58% | 6 | Apr 30, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.52 | +360.53% | 1 | Mar 5, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $84.00 | +30.95% | 4 | Feb 28, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $564.28 | +28.48% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $11.75 | - | 1 | May 7, 2024 |
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $45.12
Upside: +17.46%
AtriCure
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $42.38
Upside: +41.58%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.52
Upside: +360.53%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $84.00
Upside: +30.95%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $564.28
Upside: +28.48%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $11.75
Upside: -